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Abstract
We had previously reported that Acanthamoeba castellanii (ACA) contains a mimicry epitope for proteolipid protein 139–151
capable of inducing central nervous system (CNS) autoimmunity in SJL/J mice. We now present evidence that ACA also contains a mimicry epitope for myelin basic protein (MBP) 89–101, a derivative from amoebic nicotinamide adenine dinucleotide
dehydrogenase subunit 2 (NAD). The epitope, NAD 108–120, contains a discontinuous stretch of six amino acids in the core
region (VVFFKNIILIGFL) sharing 46% identity with MBP 89–101 (VHFFKNIVTPRTP; identical residues are underlined). SJL
mice immunized with NAD 108–120 develop encephalomyelitis similar to the disease induced by the cognate peptide. We
demonstrate that NAD 108–120 induces T cells that cross-react with MBP 89–101; the antigen-sensitized T cells, which produce
predominantly T helper (Th) 1 and Th17 cytokines, transfer disease in naive SJL recipients reminiscent of the disease induced
with MBP 89–101. This is the first report to demonstrate that a solitary microbe can induce CNS autoimmunity by generating
cross-reactive T cells for multiple myelin antigens.
Keywords: Experimental autoimmune encephalomyelitis, Multiple sclerosis, Molecular mimicry, Myelin basic protein, Acanthamoeba castellanii
Introduction
Multiple sclerosis (MS) is believed to be an autoimmune
disease of the central nervous system (CNS), and autoreactive T cells and B cells have been implicated in the disease
pathogenesis (1, 2). Three candidate autoantigens—myelin
proteolipid protein (PLP), myelin basic protein (MBP) and
myelin oligodendrocyte glycoprotein (MOG)—have been
identified in MS pathogenesis, and MS patients show varying degrees of T cell and antibody responses to all three (1,
3–5). The importance of these antigens has been well studied
in the rodent models of experimental autoimmune encephalomyelitis (EAE) by inducing the disease with the immunodominant epitopes of myelin antigens, the phenotypes of
which vary with different genetic backgrounds. For example,
MBP Ac 1–11 induces the monophasic form of EAE in B10.PL
or PL/J mice (IAu); MOG 35–55 induces the chronic progressive form in C57BL/6 mice (IAb) and PLP 139–151 induces
relapsing remitting paralysis, whereas MBP 89–101 induces
the chronic or relapsing form of EAE in SJL mice (IAs) (6–11).
Likewise, the MBP fragment encompassing 89–101/87–99,
restricted by the MHC class II allele RT1D, induces the monophasic form of EAE in Lewis rats (11). These phenotypes resemble some of the clinical features of MS, thus making the
observations seen in rodents relevant to humans.
Exposure to environmental microbes such as viruses and
bacteria has long been suspected in the initiation of MS, but

direct evidence has not been proven clinically. MS epidemics
have been shown to be primarily associated with exposure to
virus infections, and the roles of human herpes virus (HHV)6 and Epstein-Barr virus (EBV) are being actively investigated (12–14). It has been suggested that microbial infections
can lead to bystander activation (15, 16) or de novo generation of autoreactive cells as a result of the release of cryptic
antigenic determinants and/or epitope spreading in infected
individuals (17). Alternatively, microbial products bearing
the sequences identical to those in self-antigens can lead to
the generation of cross-reactive cells, a phenomenon known
as molecular or antigenic mimicry (18).
In our efforts to identify the disease-inducing microbial
mimics for PLP 139–151, we recently identified a novel
epitope from Acanthamoeba castellanii (ACA), 83–95, which
induces EAE in SJL mice by generating cross-reactive cells
for PLP 139–151 (19). We also demonstrated that the pathogenicity of ACA 83–95-induced PLP-specific cells differs by
gender but is independent of cytokine responses, in that the
cross-reactive cells generated in males fail to induce the disease in females but not vice versa, suggesting modulation
of cross-reactive immune responses by sex hormones (20).
Regardless of gender, however, the TCR vβ usage of crossreactive T cells induced with ACA 83–95 differs from that
of cells induced with PLP 139–151. By using PLP 139–151/
IAs tetramers, we showed that the TCR vβ2-expressing PLP
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139–151-specific CD4 cells are skewed in mice immunized
with ACA 83–95, indicating that exposure to microbial mimics can lead to the selective expansion of T cell clones that
differ from those generated by cognate epitopes (20). In this
report, we present evidence that ACA also contains a mimicry epitope for MBP 89–101 and that the epitope spanning
108–120 amino acids represents the nicotinamide adenine dinucleotide dehydrogenase subunit 2 (NAD) of Acanthamoeba.
We demonstrate that NAD 108–120 induces clinical and histological features of EAE similar to those induced by the cognate peptide in SJL mice by generating cross-reactive T cells
for MBP 89–101 and pro-inflammatory cytokines that favor
CNS autoimmunity.
Methods
Mice
Four- to -six-week-old female SJL/J (H-2s) mice were obtained from the Jackson Laboratory (Bar Harbor, Maine,
U.S.A.). The mice were maintained in accordance with the
animal protocol guidelines of the University of NebraskaLincoln, Lincoln, Nebraska, U.S.A.
Identification of NAD 108–120
Using the LALIGN server (http://www.ch.embnet.org/
software/LALIGN_form.html), we searched for identical
sequences of MBP 89–101 (VHFFKNIVTPRTP) by comparing ~200 known protein sequences of ACA retrieved from
National Center for Biotechnology Information protein database (http://www.ncbi.nlm.nih.gov/). This search resulted
in the identification of one epitope spanning the amino acids 108–120 within the NAD of ACA (VVFFKNIILIGFL). All
the data were generated using NAD 108–120, except for the
homology model for which we used the sequence of NAD
104–118 (NDAAVVFFKNIILIG) by including four additional
residues at the N-terminal end and excluding two residues at
the C-terminal end from NAD 108–120. The sequence length
of NAD 104–118 is consistent with that of MBP 85–99 used in
the structural study (21).
Derivation of NAD 104–118/HLA-DR2 homology model
To determine differences between MBP 85–99 and NAD
104–118 with respect to their MHC-contact residues within
the binding pockets of HLA-DR2 molecule, we used the crystal structure of HLA-DR2 (DRA, DRB1*1501) complexed with
human MBP 85–98 or MBP 86–99 as a reference model (21).
The coordinates of these structures (1BX2) were obtained from
the Research Collaboratory for Structural Bioinformatics Protein Data Bank (http://www.rcsb.org) and used with the kind
permission from Dr. Kai Wucherpfennig, Harvard University,
Boston, Massachusetts, U.S.A. The MBP 85–99 reference model
was generated by averaging the monomers from the original
crystal structure complexed with MBP 85–98 for one monomer and with MBP 86–99 for the other. The averaged structure
was three dimensional-protonated and energy-minimized
using MMFF94x restraints within MOE software to yield an
optimized MBP 85–99/HLA-DR2 structure (Chemical Computing group, Montreal, Canada). The optimized MBP 85–99/
HLADR2 model was then used as a template to generate a homology model for HLA-DR2 molecule complexed with NAD
104–118, and the structure was optimized using MOE as described above. The figures of the model were generated using

PyMOL software (http://www.pymol.org).
Peptide synthesis and immunization procedures
NAD 108–120, MBP 89–101 and Theiler’s murine encephalomyelitis virus (TMEV) 70–86 (WTTSQEAFSHIRIPLP) were
synthesized on 9-fluorenylmethyloxycarbonyl chemistry
(Neopeptide, Cambridge, Massachusetts, U.S.A.). All peptides were HPLC-purified (>90%) and confirmed by mass
spectroscopy and then dissolved in sterile 1× PBS (MBP 89–
101) or 1× PBS/dimethyl sulfoxide (DMSO) (NAD 108–120).
For disease induction, peptides dissolved in 1× PBS were
emulsified in complete Freund’s adjuvant (CFA) supplemented with Mycobacterium tuberculosis (MTB) H37RA extract (Difco Laboratories, Detroit, Michigan, U.S.A.) to a final
concentration of 5 mg ml1, and the peptide emulsions were
administered twice in the sternal and inguinal regions with
an interval of 7 days (6). In addition, pertussis toxin (PT; List
Biological Laboratories, Campbell, California, U.S.A.) was
administered (400 ng per mouse) intraperitoneally on day 0
and day 2 post-immunization after the first immunization (6,
8, 22) only. To measure recall responses, MBP 89–101 and
NAD 108–120 dissolved respectively, in 1× PBS and DMSO
were emulsified in CFA containing no additional MTB extract and administered as above.
Clinical scoring and histopathology
After EAE induction, the mice were monitored for clinical
signs of disease and scored as described previously (8, 22):
0, healthy; 1, decreased tail and body tone; 2, a clumsy but
otherwise normal gait; 3, definite weakness of one or more
limbs; 4, a paraplegic or monoplegic state and 5, a premorbid state. Animals were euthanized during recovery or upon
termination on day 30 post-immunization. Brain and spinal
cords were collected in 10% phosphate-buffered formalin and
analyzed for histological evidence of inflammatory changes
(19, 23). After fixation, two brain sections were made; one included cerebrum and hippocampus, and the second included
cerebellum and brainstem. In the spinal cord, three sections
were made from each segment (cervical, thoracic, lumbar
and sacral). All the tissues were stained by hematoxylin and
eosin staining. Tissues were blinded to treatment, lesion type
was characterized and severity was scored. Severity scores
were obtained by counting inflammatory foci in both meninges and parenchyma for all sites. Inflammation was primarily classified as lymphocytic, suppurative or mixed (19, 20).
For statistical analysis, counts were added across all sections
of brain and spinal cord for each mouse.
Adoptive transfer EAE
Groups of five mice were immunized twice with MBP 89–
101 or NAD 108–120 (200 μg per mouse) with a 7-day interval
between immunizations; 7 days after the second immunization, the animals were killed, and LNC were prepared from
the draining lymph nodes (LNs). LNC were stimulated with
Concanavalin-A (Con-A) at a concentration of 1 μg ml-1 for
2 days as described previously (6, 24). Viable lymphoblasts
were harvested by Ficoll-Hypaque density-gradient centrifugation, and 60 × 106 cells were administered intraperitoneally
into groups of five naive SJL mice. Additionally, each animal
received PT (400 ng) on days 0 and 2 post-transfer, and the
animals were monitored for clinical signs of EAE and scored
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as above (8, 22, 6). The experiments were terminated on day
21 postinoculation, and the CNS tissues were harvested for
histology (19, 20).
Proliferation assay
Groups of mice were immunized with MBP 89–101 or NAD
108–120, and after 10 days, the animals were killed and the
draining LN collected to prepare single-cell suspensions.
LNC were stimulated with MBP 89–101, NAD 108–120 and
TMEV 70–86 (0–100 lgml1) at a cell density of 5 × 106 cells/
ml for 2 days in RPMI medium supplemented with 10% fetal
bovine serum, 1 mM sodium pyruvate, 4 mM L-glutamine,
1× each of nonessential amino acids and vitamin mixture
and 100 U/ml penicillin–streptomycin (Lonza, Walkersville,
Maryland, U.S.A.). Cultures were then pulsed with 1 μCi of
tritiated 3[H]thymidine per well; 16 h later, the proliferative
responses were measured as counts per minute (c.p.m.) using
a Wallac liquid scintillation counter (Perkin Elmer, Waltham,
Massachusetts, U.S.A.) hereafter called growth medium. We
further verified these responses by second-round of re-stimulation with each peptide. LNC obtained from immunized
mice were first stimulated with MBP 89–101 or NAD 108–
120 (20 μg ml-1) for 2 days and the cells were maintained in
growth medium containing IL-2. Viable cells were harvested
on day 4 post-stimulation; rested for ~10 to 14 days and the
proliferative responses were measured after re-stimulating
the cells with the indicated peptides as above.
Intracellular cytokine staining
Mice were immunized with MBP 89-101 or NAD 108–120
and 10 days later, the animals were killed and LN were harvested to prepare LNC. Cells were stimulated with the corresponding peptides for 2 days (20 μg ml-1) and the cultures
were maintained in IL-2 medium. Viable lymphoblasts were
harvested on day 4 and stimulated for 4.5 h with phorbol
12-myristate 13-acetate (PMA) (20 ng ml-1) and ionomycin
(300 ng ml-1) (Sigma–Aldrich, St Louis, Missouri, U.S.A.) in
the presence of 2 mM monensin (GolgiStop; BD Pharmingen,
San Diego, California, U.S.A.). After staining with anti-CD4
and 7-aminoactinomycin D (7-AAD; Invitrogen, Eugene, Oregon, U.S.A.), cells were fixed, permeabilized and stained
with cytokine antibodies or isotype controls (eBioscience,
San Diego, California, U.S.A.; 19, 20). Cells were acquired
by flow cytometry (FC, FACS Scan; BD Pharmingen), and
the frequencies of cytokine-secreting cells were analyzed in
the live (7-AAD) CD4+ subset using Flow Jo software (Tree
star, Ashland, Oregon, U.S.A.; 19). The clones of cytokine
antibodies used were: IL-2 (JES6-5H4), IL-4 (11B11), IL-10
(JES5-16E3), IFN-γ (XMG1.2), IL-17A (eBio 17B7), IL-17F
(eBio 18F10), granulocyte macrophage-colony stimulating
factor (GM-CSF) (MP122E9) (all from eBioscience) and IL-22
(140301) (R&D Systems, Minneapolis, Minnesota, U.S.A.).
Cytokine ELISA
Supernatants harvested from the above cultures on day 2
were analyzed for cytokines by ELISA (19). The clones of the
capture and detection antibody pairs used were: IL-2 (JES61A12/JES6-5H4), IL-4 (11B11/BVD6-24G2), IL-10 (JES516E3/JES5-2A5), IL-17A (eBio17CK15A5/eBio17B7), IFN-γ
(AN-18/R4-6A2), IL-22 (1H8-PWSR/IL-22-JOP) and GMCSF (MP1-22E9/MP1-31G6) (eBioscience).
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Analysis of TCR vβ usage
LNC harvested from the mice immunized with MBP 89–
101 or NAD 108–120 were stimulated with the corresponding peptides for 2 days (20 μg ml-1), and the cultures were
maintained in IL-2 medium. Cells were harvested on day 4
post-stimulation with peptides and stained with a panel of
anti-mouse TCR vβ antibodies: vβ 2, 3, 4, 5.1, 5.2, 6, 7, 8.1,
8.2, 8.3, 9, 10b, 11, 12, 13, 14 and 17a (BD Pharmingen), antiCD4 and 7-AAD. After acquiring the cells by FC, percentages
of TCR vβ+ cells were enumerated in the live (7-AAD-) CD4
population (20).
Statistics
Comparisons of histological disease between groups for inflammatory lesions in the brain and spinal cords were analyzed by two-sided Wilcoxon rank sum test (Mann–Whitney
U-test). Differences in the cumulative neurological scores
of animals with EAE and cytokine secretion with respect to
T helper (Th)1, Th 2 and Th17 subsets between groups were
compared by student’s t-test. P < 0.05 values were considered significant.
Results
NAD 108–120 has the structural characteristics of binding to
HLA-DR2 molecules
By sequence comparisons, we identified NAD 108–120 as
the mimicry epitope for MBP 89–101 showing a similarity of 46.2% and containing a discontinuous stretch of six
amino acids (VVFFKNI) in the core region [Figure 1A(i)].
This region within human MBP 85–99 represents an epitope
center for recognition by both TCR and auto-antibodies (5).
Further more, by crystal study of HLA-DR2 (DRA*0101,
DRB1*1501) complexed with human MBP 85–99, the critical
MHC-contact residues in MBP 85–99 have been well characterized (21). These include Val89 and Phe92 as primary
anchor residues, the latter being the most critical and they
bind to P1 and P4 pockets, respectively, in the HLA-DR2
molecule. Three other amino acids, Asn94, Ile95 and Thr97,
were identified as the secondary MHC-contact residues
binding to the P6, P7 and P9 pockets, respectively (21).
Both MBP 85–99 and NAD 104–118 have identical residues
in all the above positions, except that Thr97 in MBP 85–99
is substituted with Leu116 in NAD 104–118 [Figure 1A(ii)].
To understand the structural characteristics of MHC binding, we derived a homology model for NAD 104–118/
HLA-DR2, which agreed well with the reference structure
(Figure 1B), with an overall root mean square deviation of
0.70 Å for all atoms (Figure 1C). Expectedly, the side chains
of the conserved Phe 92/111 in MBP 85–99/NAD 104–118
superposed well, and the distance between their alpha
carbon atoms was 1.3 Å (Figure 1D). Likewise, while the
orientation of Asn (94/113) in MBP 85–99/NAD 104–118
was comparable (1.4 Å), the side chains of Val (89/108)
and Ile (95/114) were shifted, and their C-alpha positions
were 3.2 and 1.5 Å, respectively (Figure 1D). The position
shifts were consistent with energy minimization, and all
the identical residues retained their ability to bind in appropriate pockets. The homology model also provided additional information on TCR-contact residues. Previously,
it was shown that Phe91 and Lys93 in MBP 85–99 are the
major TCR-contact residues, whereas His90 is less criti-
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Figure 1. Derivation of homology model for NAD 104–118/HLA-DR2 complex. (A) Comparison of peptide sequences. Amino acid sequences
were compared with respect to NAD 108–120 versus mouse MBP 89–101 (i) and NAD 104–118 versus human MBP 85–99 (ii). Identical sequences
are underlined. Top arrows, TCR-contact residues; bottom arrows, MHC-anchor residues. Solid arrows, major contacts; dotted arrows, minor
contacts. (B) MBP 85–99/HLA-DR2 reference model. The MBP 85–99/HLA-DR2 (DRA, DRB1*1501) reference model was generated by averaging the monomers from the original crystal structure complexed with MBP 85–98 or MBP 86–99 as described in the Methods, and the figure was
generated in PyMOL software. (C) NAD 104–118/HLA-DR2 homology model. Using MBP 85–99/HLA-DR2 reference model as a template,
homology model for NAD 104–118 complexed with HLA-DR2 was generated as above. (D) Superposition of MBP 85–99 and NAD 104–118.
The NAD 104–118/HLA-DR2 complex was superposed over MBP 85–99/HLA-DR2 reference model and the figure was generated in PyMOL
software. Solid circles, MHC-binding residues correspond to the indicated pockets (P1, P4, P6, P7 and P9) within HLA-DR2 molecule; dotted
circles, TCR-binding residues.

cal for TCR binding (5). The structure of the MBP 85–99/
HLA-DR2 complex also revealed that these residues were
exposed, allowing them to be easily accessible to TCR (21).
Similar to MBP 85–99, NAD 104–118 also has the two major
TCR-contact residues, Phe110 and Lys112, whereas His90 is
substituted with Val109 [Figure 1A (ii)]. Among these two
common residues, the homology model shows that the side
chains of Phe91/110 superpose almost identically, whereas
Lys (93/112) is more flexible (Figure 1D). Taken together,
the homology model suggests that the most critical residue,
Phe at positions 111 and 110 in NAD 104–118, is expected to
interact with the P4 pocket of the HLA-DR2 molecule and
TCR, respectively.

NAD 108–120 induces EAE similar to MBP 89–101
To determine the disease-inducing ability of NAD 108–120,
we used active immunization and adoptive transfer EAE
protocols. We immunized groups of mice and followed the
disease course for 30 days. The CNS tissues were collected
for histology during remission or upon termination of experiments. We noted that NAD 108–120 induced the disease dose
dependently ,in that a dose of 50 μg per mouse did not induce
the disease, whereas the disease severity was moderate in
animals that received 100 μg (Figure 2A). In contrast, a dose
of 200 μg NAD 108–120 resulted in EAE severity comparable
to that induced by MBP 89–101, with a similar mean day of
onset (12.00 ± 1.32 versus 12.10 ± 0.94) and mean maximum
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score (1.90 ± 0.23 versus 2.00 ± 0.15) [Table 1(i)], including the
cumulative scores (16.00 ± 2.54 versus 18.00 ± 2.87) [Figure
2C(i)]. Consistent with clinical EAE, mice that received NAD
108–120 showed dose-dependent perivascular infiltrations
in the brains and spinal cords, and the inflammatory foci
in animals that received 200 μg of NAD 108–120 were comparable to those immunized with MBP 89–101 [Table 1(i)].
Likewise, regardless of the immunogens used, inflammatory changes were found in both meninges and parenchyma,
with a tendency for lesions to be seen more in meninges than
parenchyma as evaluated at different time points (day 16 or
30) post-immunization, and the infiltrations were composed
predominantly of lymphocytes, with few histiocytes and
plasma cells [Figure 3A]. Verification of these results in naive
mice did not reveal any of the changes described above (data
not shown). We next verified encephalitogenic potential of
NAD 108–120 in adoptive transfer experiments by injecting
the lymphoblasts obtained from mice immunized with the
corresponding peptides as described previously (24, 25). As
shown in Figure 2B, LNC from mice immunized with MBP
89–101 or NAD 108–120 induced the disease in all the naive
SJL recipients (100%) with comparable mean days of onset
(11.40 ± 0.51 versus 11.80 ± 0.73) and mean maximum scores
(2.20 ± 0.20 versus 2.00 ± 0) [Table 1(ii)]. The disease severity,

Figure 2. NAD 108–120 induces autoimmune encephalomyelitis
similar to MBP 89–101. (A) EAE induction by active immunization.
Groups of SJL mice were immunized with the indicated amounts
of MBP 89–101 or NAD 108–120 in CFA twice with an interval of
1 week and PT was administered on day 0 and 2 after the first immunization. The mice were monitored for clinical signs of EAE and
scored. (B) EAE induction by adoptive transfer. Seven days after the
second immunization with MBP 89–101 or NAD 108–120, the mice
were killed and LNC were harvested from the draining LN. LNC
were stimulated with Con-A for 2 days and viable lymphoblasts
were injected into naive SJL mice intraperitoneally. Each mouse received PT (400 ng) on day 0 and 2 post-transfer and the animals
were observed for signs of EAE and scored. Mean values for a group
of mice are shown. (C) Cumulative scores. Cumulative scores were
obtained by adding the neurological scores for each mouse and
compared between groups. Each bar represents mean ± SEM values
for a group of mice.
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however, tended to be lower in mice that received cells from
NAD 108–120 than those that received MBP 89–101 sensitized cells as evaluated based on cumulative scores (12.60 ±
1.69 versus 16.60 ± 1.81) [Figure 2C(ii)] and the inflammatory
foci in CNS tissues [Table 1(ii); Figure 3B]. Taken together,
the data suggest that NAD 108–120 is an encephalitogenic
mimicry epitope of MBP 89–101 and disease induction requires the mediation of antigen-sensitized T cells.
MBP 89–101 and NAD 108–120 induce cross-reactive T-cell responses
Induction of EAE with MBP 89–101 in SJL mice is typically mediated by CD4 cells (8, 22, 26). The fact that CNS
inflammation induced by NAD 108–120 was similar to that
induced by MBP 89–101 suggests that the mimicry epitope
can induce the generation of cross-reactive T cells for MBP
89–101. To examine this possibility, we stimulated LNC
from mice immunized with NAD 108–120 or MBP 89–101
with the corresponding peptides dissolved in 1× PBS, and
their recall responses were measured based on 3[H]thymidine incorporation. Expectedly, both MBP 89–101 and NAD
108–120 induced the dose-dependent proliferative responses
to the respective peptides, but a fraction of these cells also responded to unimmunizing peptides (Figure 4). For example,
LNC from MBP 89–101 immunized mice responded to MBP
peptide, and approximately one-third of the MBP-reactive T
cells also showed response to NAD 108–120 [Figure 4A (i)].
Similar patterns were observed when NAD 108–120 sensitized LNC were examined for their reactivity to NAD and
MBP peptides although the reactivity for the latter was relatively low [Figure 4A(ii)]. The responses were antigen specific since LNC from mice immunized with either MBP 89–
101 or NAD 108–120 did not respond to the control peptide
(TMEV 70–86). We verified these data by second-round of restimulation with MBP 89–101 or NAD 108–120. Expectedly,
LNC cultures prepared from MBP 89–101 immunized mice
responded dose dependently to both MBP 89–101 (7.9-fold)
and NAD 108–120 [4.9-fold; Figure 4B(i)]. Similar patterns
were noted when the cultures obtained from NAD 108–120
immunized mice were re-stimulated with NAD 108–120 (2.9fold) and MBP 89–101 [2.8-fold; Figure 4B(ii)]. The data demonstrate that MBP 89–101 and NAD 108–120 induce antigenspecific cross-reactive T-cell responses.
LNC sensitized with MBP 89–101 or NAD 108–120 produce cytokines that favor CNS autoimmunity
The hallmark of encephalitogenic T cells is their ability to
secrete Th 1 and Th17 cytokines; in addition, mice deficient in
GM-CSF show resistance to the development of EAE (27–29).
We examined Th1 (IL-2 and IFN-γ), Th2 (IL-4 and IL-10),
Th17 (IL-17A, IL-17F and IL-22) cytokines and GM-CSF in
LNC obtained from mice immunized with MBP 89–101 or
NAD 108–120 by both intracellular cytokine detection and
cytokine ELISA. Figure 5(A) shows that the cells capable of
secreting all the cytokines tested except IL-4 were present in
the cultures stimulated with MBP 89–101 or NAD 108–120.
Their proportions were dominated by both Th1 (12.25 ± 2.14
versus 11.18 ± 2.65) and Th17 (9.05 ± 1.32 versus 6.13 ± 1.23)
cytokine-secreting cells (Figure 5A and B). Within the Th17
subset, however, frequencies of IL-22secreting cells were
higher than IL-17F and IL-17A or combination of the two
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Table 1. Clinical and histologic EAE in SJL mice induced with MBP 89–101 and NAD 108–120a
Treatment 				 Clinical disease 																																	 No. of inflammatory foci
										 Incidence (%) 			 Mean day of onsetb 			 Mean maximum scoreb 				 Meninges 				 Parenchyma 					 Total
(i) EAE induction by active immunization
MBP 89–101
200 μg 							 9/11 (81.8) 					 12.10 ± 0.94 								2 ± 0.15 												4.18 ± 1.36 					2.27 ± 0.75 							 6.45 ± 2.01
NAD 108–120
50 μg 								 2/4 (50) 										 0 												0 																 1 ± 0.71 							0 ± 0 									 1 ± 0.71
100 μg 						 3/4 (75) 									14 ± 0.00 								1 ± 0.00 												 6.5 ± 4.57 				 0.75 ± 0.48 							 7.25 ± 4.99
200 μg 							11/11 (100) 								12 ± 1.32 						 1.09 ± 0.23 												9.09 ± 3.80 					3.73 ± 1.14 							12.82 ± 4.53
(ii) EAE induction by adoptive transfer
MBP 89–101 				 5/5(100) 								11.4 ± 0.51 							2.2 ± 0.2 													10.4 ± 6.65 						11 ± 7.07 							 21.4 ± 13.69
NAD 108–120 			 5/5(100) 								11.8 ± 0.73 								2 ± 0 														 6 ± 2.51 					 1.4 ± 0.93 							 7.4 ± 2.04
Scoring scale: 0, healthy; 1, decreased tail and body tone; 2, a clumsy but otherwise normal gait; 3, definite weakness of one or more limbs; 4, a
paraplegic or monoplegic state; 5, a premorbid state.
a
Numbers are mean ± SEM.
b
Represents only mice that showed clinical disease.

(Figure 5A). Nonetheless, comparison of MBP-versus NADstimulated cultures for frequencies of cells producing different cytokines did not reveal any striking differences except
that Th17 cytokine-secreting cells tended to be low in NAD
108–120 cultures. Verification of these results by cytokine
ELISA revealed no detectable amounts of IL-4, but Th1 and
Th17 cytokines were detected with no skewing toward IL22 secretion (Figure 5C). Comparative analysis revealed
that MBP 89–101 stimulated culture supernatants had more
of both Th1 and Th17 cytokines, including GM-CSF, than
those from NAD 108–120 sensitized cultures; the respective
amounts were 701.36 ± 169.19 versus 72.50 ± 30.94; 451.51 ±
77.99 versus 45.23 20.73 and 128.58 ± 48.59 versus 8.00 ± 2.25
pg (P ≤ 0.001). Taken together, the data suggest that NAD
108–120 can induce the generation of Th1 and Th17 cytokinesecreting cells but to a lesser magnitude than MBP 89–101.
T cells sensitized with MBP 89–101 or NAD 108–120 use similar
TCR vβs
To determine whether T cells sensitized with cognate and
mimicry epitopes use similar TCR vβs, we analyzed their usage in CD4 T cells in cultures prepared from mice immunized with the corresponding peptides by FC. We noted that
expression of TCRvβs were found consistently in the order of
vb4, vb2, vb17a, vβ6, vβ14, vβ3, vβ7, vβ5.1 and vβ5.2 in the
cultures stimulated with either MBP 89–101 or NAD 108–120
(Figure 6). While, the vβ usage was mostly constituted by
vβ4, vβ2, vβ17a, vβ6 and vβ14, there were no significant differences between the cultures stimulated with MBP 89–101 or
NAD 108–120 (59.45 versus 57.56%), suggesting that cognate
and mimicry epitopes sensitize similar T-cell repertoires.
Discussion
In this report, we present evidence that NAD 108–120 induces autoimmune encephalomyelitis through the generation of
cross-reactive T cells for MBP 89–101. MBP is one of the major
candidate autoantigens identified in EAE/MS pathogenesis
(2, 30). The mouse MBP sequence spanning amino acids 89–
101 has been shown to induce EAE in SJL mice (8, 31, 32), and
the human MBP 85–99 sequence equivalent to mouse MBP
89–101 matches 100%. Numerous studies indicate that T cells
and B cells from MS patients show reactivity to MBP; in addition, MBP 85–99 has been recognized as one of the major immunodominant epitopes in MS patients bearing HLA-DR2
haplotype (HLA-DRB*1501, DQB1*0602) (5, 33, 34). Indeed,

the core motif of the 10-amino acid fragment within MBP 85–
99 (VVHFFKNIVT) represents an epitope center for recognition by both MHC/TCR and auto-antibodies; for the latter,
however, the FFK sequence has to be conserved (5). Similar to
MBP 85–99, NAD 108–120 also possesses all the major MHCand TCR-contact residues but the question is whether it can
elicit cross-reactive T cells and trigger CNS autoimmunity in
humans. To address this possibility, we derived a homology
model for NAD 104–118/HLA-DR2 to determine whether
the configuration and orientations of the critical MHC-and
TCR-contact residues in cognate and mimicry epitopes follow similar patterns. The homology model indicated that
orientation of the side chains of the two critical MHC-anchor
residues Ph92/111 and Asn94/113 and one major TCR-contact residue, Phe91/110 in MBP 85–99/NAD 104–118 superposed comparably suggesting that the mimicry epitope can
potentially anchor HLA-DR2 molecule similar to MBP 85–99
and also to be recognized by MBP 85–99 specific TCR. We
also propose that NAD 108–120 has the potential to activate
MBP-specific B cells. We make this prediction because the
stretch of three amino acids, FFK within the epitope center
of MBP 85–99 (VVHFFKNIVT) is highly critical for MBPspecific auto-antibody recognition (5). Ironically, microbial
peptides bearing sequences identical to the epitope center
of MBP 85–99 have been previously shown to bind MBPspecific auto-antibodies derived from MS brain tissue and
the binding correlated with the number of identical residues
in the epitope center (5). These include one peptide from L2
protein of human papillomavirus (VHFFK-I), which bound
best to MBP-specific antibody followed by the peptides derived from Bacillus subtilis (FFKNI) and Clostridium cellulare
(FFKN). The fact that NAD 108–120 also possesses identical
residues similar to the above (V-FFKNI) suggests that NAD
108–120 can also bind to MBP-specific auto-antibodies.
In this study, using both active and AT-EAE protocols, we
show that NAD 108–120 induces autoimmune encephalomyelitis in SJL mice by generating cross-reactive T cells for MBP
89–101 and the T cells preferentially produce Th1 and Th17
cytokines that favor CNS autoimmunity. The induction of
cross-reactive T cell responses was expected because the core
region of NAD 108–120 has a high degree of similarity with
MBP 89–101. This region potentially contains critical MHC–
TCR-contact residues as shown in human MBP 85–99 (21),
which might have led to the generation of cross-reactive T
cells for MBP. However, the inflammatory foci in the CNS
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Figure 4. MBP 89–101 and NAD 108–120 induce cross-reactive T-cell
responses. (A) First-round stimulation. Groups of mice were immunized with MBP 89–101 or NAD 108–120 and 10 days later, animals
were killed and the draining LN were collected. LNC were stimulated with the indicated peptides for 2 days followed by pulsing with
3
[H]thymidine, the incorporation of which was measured as c.p.m.
16 h later. TMEV 70–86, control. Mean ± SEM values for a group
of mice are shown each involving up to five mice per group (MBP
89–101, n =7; NAD 108–120, n = 4). (B) Second-round stimulation.
LNC obtained from MBP 89–101 or NAD 108–120 immunized mice
were stimulated with the respective peptides twice with an interval
of approximately 10–14 days as described in the Methods and the
proliferative responses were measured as above. Mean ± SEM values for a group of mice each involving two to three mice are shown
(MBP 89–101, n =3; NAD 108–120, n =4).
Figure 3. Histological evaluation of CNS inflammation induced
with MBP 89–101 or NAD 108–120. (A) EAE induction by active
immunization. Brains and spinal cords harvested on day 16 and
day 30 from mice immunized with MBP 89–101 or NAD 108–120
show perivascular lymphocytic infiltrations (arrows) as evaluated
by hematoxylin and eosin staining. (B) EAE induction by adoptive
transfer. Hematoxylin and eosin sections show mixed perivascular
cuffing (arrows) in the brains and spinal cords of mice that received
lymphocytes generated from mice immunized with MBP 89–101 or
NAD 108–120. Original magnification, 3400 (bar = 20 μm).

lesions induced by these cells tended to be low [Table 1(ii)],
which may be due to the presence of a low proportion of Th17
cytokine-secreting cells (Figure 5). Both Th1 and Th17 cells are
critical to the mediation of CNS autoimmunity (27, 28), but
the proportion of cytokines produced by each subset appears
to be antigen dependent. For example, in our hands, we noted that antigen-specific cells from SJL mice immunized with
PLP 139–151 secrete a higher proportion of both IFN-γ and
IL-17, with a tendency for IFN-γ to be higher than IL-17, as

evaluated using IAs/PLP 139–151 tetramers (20). Although
cytokines induced with MBP 89–101 or NAD 108–120 follow
the same pattern as above, the IL-22-secreting cells dominated Th17 responses. While IL-17 and IL-22 participate in
innate immune responses (35, 36), IL-22 can exert both proand anti-inflammatory effects, but the role of IL-22 in organspecific autoimmune diseases is controversial. For example,
IL-22 potentiates chronic inflammatory diseases such as
arthritis, inflammatory bowel disease and psoriasis but not
CNS inflammation in the mouse model of EAE (37–41). Endothelial cells in the blood-brain barrier, however, express
receptors for IL-17 and IL-22, and both cytokines can promote CD4 T-cell recruitment in MS lesions (42). On the contrary, IL-22 mediates protection in T-cell-mediated hepatitis
and autoimmune myocarditis (40, 43, 44). The finding that
IL-22 is a T-cell-derived cytokine, the receptors for which are
abundantly expressed in the non-lymphoid tissues, suggests
that IL-22 can modulate inflammatory responses in the local
milieu (36). Alternatively, multiple cytokines might cooperatively regulate CNS inflammation.
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Figure 5. MBP 89–101 and NAD 108–120 induce similar cytokine profiles. (A) Intracellular cytokine staining. LNC obtained from mice immunized with MBP 89–101 and NAD 108–120 were stimulated with the corresponding peptides for 2 days and the cultures were maintained in
IL-2 medium for additional 2 days. Viable lymphoblasts were harvested and stimulated for ;4.5 h with PMA and Ionomycin in the presence of
GolgiStop and the cells were stained with anti-CD4 and 7-AAD. After fixation and permeabilization, the cells were incubated with cytokine antibodies and the frequencies of cytokine-secreting cells were determined by FC in the live (7-AAD) CD4 subset. (B) Comparison between Th1, Th
2 and Th17 cytokine-secreting cells. Frequencies of CD4 cells producing IFN-γ, IL-4 and IL-10 and IL-17A, IL-17F and IL-22 corresponding to the
indicated Th subsets were added together and compared between groups. (C) Cytokine ELISA. Supernatants harvested on day 2 poststimulation
prior to the addition of IL-2 medium from the above cultures were analyzed for cytokines by ELISA. Each bar in the above represents mean ±
SEM values for a group of mice.

Figure 6. MBP 89–101 and NAD 108–120 sensitized T cells show similar TCR vβ usage. Ten days after immunization with MBP 89–101
or NAD 108–120, the mice were killed and the draining LN were
collected. LNC were stimulated with the corresponding peptides
for 2 days and maintained in IL-2 medium. Cells were harvested on
day 4 post-stimulation and stained with a panel of anti-TCR vβ and
anti-CD4 and 7-AAD. After acquiring the cells by FC, percentages of
TCR vβ+CD4+ cells were determined in the live (7-AAD) population.
Each bar represents mean ± SEM values obtained from three to four
experiments each involving one to two mice per group.

We recently reported that the TCR vβ usage of cross-reactive cells for PLP 139–151 induced with ACA 83–95 differs
from those induced with PLP 139–151, suggesting a possibil-

ity that cognate and mimicry epitopes sensitize distinct T-cell
clones (20). One possibility could be that skewed expansion
of T-cell clones expressing particular TCR vbs influences the
disease outcome, depending on the clones’ disease-inducing
abilities. Alternatively, exposure to mimicry epitopes might
lead to the expansion of hidden clones not usually responsive to cognate peptides. To address these possibilities, we
evaluated TCR vβ usage of CD4 cells sensitized with MBP
89–101 or NAD 108–120, but we did not observe any striking
differences between the two. Nonetheless, T cells expressing
TCR vβ4, vβ2, vβ17a, vβ6, vβ14 and vβ3 were dominant in
the cultures stimulated with either peptide, and these profiles were similar to those observed in PLP 139–151-sensitized cells (20, 45, 46). The data suggest that autoreactive
T-cell responses generated in a given mouse strain tend to
follow a similar pattern of TCR vβ usage regardless of the
immunogens used.
MS is a complex disease and no known etiological agents
have been identified. Two major factors have been implicated in the initiation of the disease: genetic susceptibility
and exposure to environmental factors (2). In support of the
latter, exacerbations of MS attacks or temporal alterations in
the disease course have been linked to exposure primarily
to virus infections such as EBV and HHV-6, but the clinical evidence remains elusive (12–14). The current dogma is
that MS does not appear to follow Koch’s postulates in that
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no single organism appears to trigger MS; rather, exposure
to multiple organisms might be critical for MS predisposition (2). We recently reported that ACA contains a mimicry
epitope, ACA 83–95, for PLP 139–151, which induces a typical relapsing and remitting type of paralysis in SJL mice by
generating PLP-specific T cells (19). In this report, we present
evidence that ACA also contains a mimicry epitope, NAD
108–120, but this peptide induces EAE through the generation of T cells that cross-react with yet another myelin antigen, MBP 89–101. While ACA 83–95 is a derivative of
rhodanese-related sulfur transferase of Acanthamoeba, NAD
108–120 represents NAD, which has been recognized as one
of the virulent factors of ACA (47, 48). Presently, it is not
known whether these amoebic proteins are processed and
present ACA 83–95 and NAD 108–120 in animals infected
with Acanthamoeba. Proving that mice infected with Acanthamoeba show ACA 83–95 or NAD 108–120/NAD 104–118
reactive T cells implies that the amoebic peptides are processed and presented naturally by the APCs. There is an indication that mice infected with ACA show the generation
of myelin-and ACA-reactive T cells (Massilamany C., et al,
unpublished results). However, it has been shown that the
brains of mice infected with Acanthamoeba culbertsoni show
increased expression of amoebic NAD mRNA (47), and the
abundant availability of this amoebic protein can potentially
generate cross-reactive immune responses for MBP locally.
ACA is a natural CNS pathogen of humans, and while most
individuals are exposed to Acanthamoeba as indicated by the
presence of amoeba-reactive antibodies, they can remain
asymptomatic, but the amoebae can induce granulomatous
encephalitis in immunocompromised individuals. Whether
such exposures can lead to CNS autoimmunity in genetically
susceptible individuals remains to be tested. Based on our
homology model, we predict that MS patients showing T cell
and antibody reactivity to MBP could also react to mimicry
epitope by cross reactivity. Experiments are underway to analyze cerebrospinal fluid samples obtained from MS patients
to determine the presence of Acanthamoeba-specific genomic
material or antibodies.
In conclusion, we show that ACA, in addition to possessing
a mimicry epitope for PLP 139–151 (19), also contains NAD
108–120 as the mimicry epitope for MBP 89–101. The fact
that ACA contains two mimicry epitopes for two different
myelin antigens suggests that ACA infection can potentially
lead to the generation of multiple myelin-reactive T cells.
MS is a multifactorial disease characterized by a plethora of
symptoms in the affected individuals, and the proposal that
exposure to multiple microbes is a requirement for MS predisposition is gaining importance (2). It is tempting to speculate whether microbes similar to Acanthamoeba bearing the
mimicry sequences for multiple myelin antigens are likely
to be the candidates of disease initiation. To our knowledge,
this is the first report to demonstrate that a solitary microbe
contains mimicry sequences for more than one autoantigen
in the target organs of their natural predilection in the infected individuals. Acanthamoebae are free-living organisms
and are ubiquitous in the environment, leading to constant
exposure. It is possible that such a co-existence can help microbes acquire some of the genetic elements of their hosts as
an evasive mechanism for survival. Alternatively, exposure
to such organisms could lead to a break in self-tolerance as
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a result of antigenic mimicry in genetically susceptible individuals who potentially carry pathogenic autoreactive T-cell
and B-cell repertoires.
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